World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
62
Citations
16195
World Ranking
3118
National Ranking
1461

Rhea N. Coler publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Rhea N. Coler sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 176 publications — 25th percentile

25% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Rhea N. Coler D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Rhea N. Coler sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 62 D-Index — 37th percentile

37% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Rhea N. Coler is affiliated with the University of Washington in the United States. Their research primarily spans the fields of Medicine and Immunology and Microbiology, with a significant focus on infectious diseases and immune response mechanisms.

The scientist's subfields of study include Infectious Diseases, Immunology, Epidemiology, Molecular Biology, and Public Health, Environmental and Occupational Health. Their work extensively covers topics like Tuberculosis Research and Epidemiology, SARS-CoV-2 and COVID-19 Research, and Mycobacterium Research and Diagnosis. Other notable areas of focus involve Immunotherapy and Immune Responses, COVID-19 Impact on Reproduction, COVID-19 Clinical Research Studies, and Vaccine Coverage and Hesitancy.

Collaborations are an important aspect of their academic activity. Frequent co-authors include:

  • Sasha E. Larsen
  • Susan L. Baldwin
  • Tiffany Pecor
  • Bryan J. Berube
  • Kathleen M. Neuzil

The venues where Rhea N. Coler most often publishes reflect their research themes, which include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Frontiers in Immunology
  • Vaccines
  • New England Journal of Medicine
  • Microorganisms

Among recent papers featuring their research contributions are:

  • "An mRNA Vaccine against SARS-CoV-2 - Preliminary Report" (2020) published in New England Journal of Medicine
  • "Homologous and Heterologous Covid-19 Booster Vaccinations" (2022) published in New England Journal of Medicine
  • "Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant" (2022) published in Cell Reports Medicine
  • "Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection" (2020) published in Molecular Therapy - Methods & Clinical Development
  • "Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial" (2020) published in The Lancet Respiratory Medicine

Best Publications

  • An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

    Lisa A. Jackson;Evan J. Anderson;Nadine G. Rouphael;Paul C. Roberts

  • Homologous and Heterologous Covid-19 Booster Vaccinations

    Unknown

  • New horizons in adjuvants for vaccine development

    Steven G. Reed;Sylvie Bertholet;Rhea N. Coler;Martin Friede

  • Taking toll: lipid A mimetics as adjuvants and immunomodulators.

    David H Persing;Rhea N Coler;Michael J Lacy;David A Johnson

  • Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.

    Rhea N. Coler;Sylvie Bertholet;Magdalini Moutaftsi;Jeff A. Guderian

  • Second-generation vaccines against leishmaniasis

    Rhea N. Coler;Steven G. Reed

  • A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug Resistant Mycobacterium tuberculosis

    Sylvie Bertholet;Gregory C. Ireton;Diane J. Ordway;Hillarie Plessner Windish

  • Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

    Unknown

  • Leish-111f, a Recombinant Polyprotein Vaccine That Protects against Visceral Leishmaniasis by Elicitation of CD4+ T Cells

    Rhea N. Coler;Yasuyuki Goto;Lisa Bogatzki;Vanitha Raman

  • Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.

    Elizabeth G. Rhee;Susana Mendez;Javeed A. Shah;Chang-you Wu

  • Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens.

    Niels Peter H. Knudsen;Anja Olsen;Cecilia Buonsanti;Frank Follmann

  • Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.

    Rhea N. Coler;Yasir A. W. Skeiky;Karen Bernards;Kay Greeson

  • Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant.

    Yasir A.W Skeiky;Rhea N Coler;Mark Brannon;Erika Stromberg

  • Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.

    Antonio Campos-Neto;Renato Porrozzi;Kay Greeson;Rhea N. Coler

  • Molecular characterization and human T-cell responses to a member of a novel Mycobacterium tuberculosis mtb39 gene family

    Davin C. Dillon;Mark R. Alderson;Craig H. Day;David M. Lewinsohn

  • Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys

    Steven G. Reed;Rhea N. Coler;Wilfried Dalemans;Esterlina V. Tan

  • Identification of Human T Cell Antigens for the Development of Vaccines against Mycobacterium tuberculosis

    Sylvie Bertholet;Gregory C. Ireton;Maria Kahn;Jeffrey Guderian

  • Expression Cloning of an Immunodominant Family of Mycobacterium tuberculosis Antigens Using Human Cd4+ T Cells

    Mark R. Alderson;Teresa Bement;Craig H. Day;Liqing Zhu

  • A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis.

    Jaya Chakravarty;Subodh Kumar;Sonali Trivedi;Vijay K. Rai

  • The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.

    Rhea N. Coler;Tracey A. Day;Ruth Ellis;Franco M. Piazza

  • A synthetic adjuvant to enhance and expand immune responses to influenza vaccines.

    Rhea N. Coler;Susan L. Baldwin;Narek Shaverdian;Sylvie Bertholet

  • Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial

    Adam Penn-Nicholson;Michele Tameris;Erica Smit;Tracey A Day

Frequent Co-Authors

Steven G. Reed
Steven G. Reed Infectious Disease Research Institute
Mark R. Alderson
Mark R. Alderson Program for Appropriate Technology in Health
Yasir A. W. Skeiky
Yasir A. W. Skeiky International AIDS Vaccine Initiative
Ian M. Orme
Ian M. Orme Colorado State University
Roberto Badaró
Roberto Badaró Federal University of Bahia
David M. Lewinsohn
David M. Lewinsohn Oregon Health & Science University
Dinesh Mondal
Dinesh Mondal International Centre for Diarrhoeal Disease Research
Peter E. Andersen
Peter E. Andersen Technical University of Denmark
Jesus G. Valenzuela
Jesus G. Valenzuela National Institutes of Health
Shaden Kamhawi
Shaden Kamhawi National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens up various career opportunities in healthcare and research. For individuals interested in patient care roles that complement immunology knowledge, pursuing nursing degrees online can be an excellent pathway. Many programs of this nature are designed to accelerate your education and facilitate quicker entry into the workforce.

If you’re a non-nurse looking to transition into nursing, 12-month accelerated nursing programs online for non nurses offer an efficient route. These programs build foundational nursing skills rapidly, essential for roles that often overlap with immunology, such as clinical nursing or patient education.

For those aiming for a Bachelor of Science in Nursing, exploring accelerated BSN programs for non nurses provides a direct path to becoming a registered nurse, expanding your clinical expertise related to immune system disorders. Additionally, certified nurse practitioners can further specialize by considering accelerated NP programs, which provide advanced training and elevate your career prospects.

Alternatively, accredited LPN programs easy to get into serve as accessible entry points for individuals wanting practical nursing credentials. While these may require additional steps for immunology-related specialization, they provide valuable healthcare experience and patient interaction opportunities.

Overall, these educational pathways enhance your skill set and open doors to diverse roles in immunology research, clinical practice, and healthcare innovation.

Best Scientists Citing Rhea N. Coler

Trending Scientists

Recently Published Articles